In this study we compared the lymphocyte reconstitution in 13 multiple myeloma (MM), nine acute myeloid leukemia (AML) and 10 chronic myeloid leukemia (CML) patients after allogeneic G-CSF-mobilized PBSC transplantation from HLA-identical siblings. Conditioning regimens included standard total body irradiation + cyclophosphamide (CY), or busulphan + CY, whereas VP-16 was added in patients with advanced disease. Overall comparable numbers of mononuclear cells, CD34
Allogeneic transplantation of G-CSF-mobilized peripheral blood stem cells (PBSC) results in a rapid and complete engraftment in a large proportion of patients. [1] [2] [3] This is likely to be due to the infusion of high numbers of donor G-CSF-mobilized stem cells, as well as of lymphocytes, into allogeneic PBSC recipients. Nevertheless, despite the higher amount of T cells infused with PBSC than with marrow, allogeneic transplants with PBSC seem not to result in a significantly greater incidence of acute graft-versushost disease (aGVHD). Also, previous studies demonstrated that patients receiving allogeneic PBSC have a faster immune recovery than those receiving marrow cells. 4, 5 However, the majority of the patients included in these studies had myeloproliferative disorders, such as acute myeloid leukemia (AML), or chronic myeloid leukemia (CML), or myelodysplasia (MDS), and a few cases had lymphoproliferative disorders. In particular, only small numbers of patients with multiple myeloma (MM) have been allotransplanted in the past due to the high transplantrelated mortality. 6, 7 On the contrary, more recently a better selection of patients, together with better timing of the transplant, and/or less toxic conditioning regimens, have allowed the achievement of significantly better results in allogeneic stem cell transplantation in MM patients also. [8] [9] [10] In this study we addressed the questions of whether a different lymphocyte recovery after allogeneic transplant may occur in patients with MM as opposed to patients with AML or CML, and whether GVHD may be related to different immune reconstitution in these patients.
Patients, donors and methods
Thirty-two adult patients who underwent an allogeneic PBSC transplant from HLA-identical related donors in our institution were entered into this study. Informed consent was obtained from patients and donors using the protocols approved by our hospital's Ethical Committee.
Patients
Three groups of patients: 13 MM, 9 AML and 10 CML were prospectively evaluated for immunological recovery by flow cytometry after transplant. Previous treatments in each group included interferon-␣ or hydroxyurea for CML patients in chronic (CP) or accelerated (AP) phase, standard induction chemotherapy regimens for AML or CML in blast crisis (BC), and alkylating and/or anthracycline-based regimens for MM patients. Characteristics of the patients in each group, such as median age, disease status, conditioning regimens, graft composition and GVHD prophylaxis are shown in Table 1 . Standard regimens for conditioning were different depending on the disease as previously reported, 11 in particular total body irradiation (TBI: 10 Gy single dose) was performed in 11/12 MM patients who also received melphalan 120 mg/m 2 and cyclophosphamide (CY) 120 mg/kg, and in 1/9 AML patients receiving also Cy 120 mg/kg and etoposide (VP-16) 40 mg/kg, whereas busulphan 16 mg/kg and cyclophosphamide 200 mg/kg (BU/CY) 12 was used in CML patients as well as in 6/9 AML and 1/13 MM patients. In cases with AML in CR Ͼ1, or in relapse, or with CML in AP or BC, VP-16 (40 mg/kg) was also added to the conditioning treatment.
Acute GVHD was graded according to Przepiorka et al, 13 while chronic GVHD was classified according to the criteria described by Shulman et al. 14 GVHD prophylaxis included cyclosporin A (CsA) and short methotrexate (day +1, +3, +6 and +11), as previously described, 11 in 31 patients, and only CsA in one patient. Acyclovir, 10 mg/kg i.v. three times per day, was given from day −5 to +25, then orally for 9 months. Pre-emptive treatment of cytomegalovirus (CMV) disease was performed with i.v. or oral gancyclovir in case of CMV-positive antigenemia, tested weekly until day +120 after transplant. Table 1 Characteristics of the patients, conditioning regimens, graft composition and GVHD prophylaxis in 13 MM, 9 AML and 10 CML recipients of an allogeneic PBSC transplantation who entered into this study 
Donors
For stem cell mobilization, related HLA-identical healthy donors received glycosylated rhG-CSF (Lenograstin; Rhone-Poulenc Rorer, Milan, Italy) 10 g/kg/day on days 0 to 5 and leukaphereses were performed on days 5-7 to collect у4 × 10 6 CD34 + cells/recipient body weight, and then cryopreserved in liquid nitrogen until transplantation as previously described. 11 The overall median values of donor mononuclear cells, CD34
+ and CD3 + cells, assessed as follows, infused in each group of patients is shown in Table 1 .
Flow cytometry
Complete blood counts with differentials were performed on a 4 days per week basis for the first 30 days, every 7 or 14 days for the following 5 months and at least monthly until 1 year after transplant. Blood samples from each patient were analyzed by direct flow cytometry on the day before starting the conditioning regimen (pre) and 1, 2, 3, 6 and 12 months after allogeneic PBSC transplant to assess the immunological reconstitution.
Human monoclonal antibodies (mAbs) used in this study are the following: CD3 fluorescein isthyocianate (FITC), CD4 FITC, CD8 FITC, CD16 FITC, CD56 phycoerythrin (PE), CD57 FITC, CD19 FITC, CD34 FITC or PE and isotype controls (Becton Dickinson, San José, CA, USA). Briefly, appropriate amounts of mAbs were added to 100 l of whole blood followed by an incubation of 15 min at room temperature. Red cells were then lysed, and after washing twice 10-20 × 10 4 events were acquired on a FACScalibur instrument (Becton Dickinson) and analyzed by CellQuest software. Lymphocytes were gated on using linear side scatter (SSC) and forward scatter (FSC) characteristics to exclude monocytes. Absolute counts for each cellular fraction were calculated as the product of the absolute white blood cell (WBC) count and lymphocyte differential percentage and the cellular subset percentage as determined by immunophenotype. Flow cytometric analysis was also performed on leukapheresis products to assess the percentage and the absolute number of CD34 + hematopoietic progenitors and lymphocyte subsets in the graft.
Statistical analysis
Data are represented as median values and ranges. Analysis at each time-point was performed using the Kruskal-Wallis or the Wilcoxon-Mann-Whitney test as required, and twosided P values were reported when significant (р0.05). All statistical studies were performed using the SPSS software.
Results
Thirty-two patients with MM, or CML, or AML, receiving an allogeneic PBSC transplantation from an HLA-identical sibling were entered into this study. In each group of patients a comparable number of mononuclear cells, as well as of CD3 + T lymphocytes and CD34 + progenitor cells was infused, as shown in Table 1 . In order to evaluate the kin-etics of the immune reconstitution, the overall number of total lymphocytes, T, B and NK cell subsets of each patient were assessed before and 1, 2, 3, 6 and 12 months after allogeneic PBSC transplantation. However, of 32 patients included in the study and evaluated before receiving PBSC, the analysis of lymphocyte recovery was performed after transplant in: 31 patients at 1 and 2 months, 28 patients at 3 months, 26 patients at 6 months and 22 patients at 1 year. Causes of withdrawal were: death due to infection (n = 1 MM), or to relapse (n = 2, 1 MM and 1 AML), or to GVHD (n = 3, 1 MM and 2 AML); relapse (n = 2 CML), cerebral hemorrage (n = 1 AML); while one patient was lost at the follow-up soon after transplant.
Time to absolute neutrophil count (ANC) Ͼ500/l and to platelets Ͼ50 000/l after transplant was not significantly different among the three groups (data not shown). Ten patients without significant differences in the three groups were treated with gancyclovir for cytomegalovirus (CMV) detection, although no CMV disease was observed.
Overall lymphocyte reconstitution after allogeneic PBSC transplantation
The assessment of lymphocyte recovery was performed by flow cytometry experiments in single color direct immunofluorescence.
The overall median lymphocyte number at each timepoint considered is shown in Table 2 . Although PBSC allowed an overall rapid T lymphocyte recovery documented by CD3
+ , CD4 + and CD8 + median cell numbers, the overall CD4:CD8 ratio was still Ͻ1 1 year after transplant. On the contrary, as early as 1 month after transplant the median number of NK cells was higher than pre-transplant value, and normal numbers of B cells were achieved in the majority of the patients within 6 months after transplant (Table 2) .
Different immune reconstitution in MM, AML and CML patients
Analysis of lymphocyte reconstitution after allogeneic PBSC transplantation was performed in each group of patients separately, in order to compare the immunologic recovery observed in patients with different diseases within 1 year after transplant. Overall T cell reconstitution was Table 2 Overall kinetics of lymphocyte reconstitution in 32 patients who received an allogeneic PBSC transplantation. + T cell reconstitution were observed. In particular, MM patients recovered a median CD4 + T cell number higher than in both the other two groups as early as 2 months after infusion of allogeneic PBSC (Figure 1 ), and at 3 months after transplant the median value of CD4 + cells in MM patients (385 cells/l, range: 143-750) was significantly higher than in CML patients (138 cells/l, range: 18-518) (P = 0.01) and in AML patients (151 cells/l, range: 92-231) (P = 0.01). Importantly, 1 year after transplant MM patients still showed a greater median number of CD4 + T cells (686 cells/l, range: 342-870) as opposed to AML (190 cells/l, range: 147-296) (P = 0.01) and CML patients (261 cells/l, range: 158-1012) (P = NS). Moreover, analysis of CD8 + T cell recovery in the three groups demonstrated that CML patients showed an overall median CD8 + T cell number lower than MM and AML patients at any time-point considered (Figure 1 ), although differences did not reach significance. It is noteworthy that in this study only MM patients had a CD4:CD8 ratio Ͼ1 1 year after transplant, with a median number of CD4 + T cells/l greater than 400. NK cells, evaluated by single staining with CD16, CD56 and CD57 monoclonal antibodies, achieved high values within 1 month after transplant in each group, and further increased in the following months, as shown for CD56
+ cell median numbers in Figure 1 . Finally, while the overall B lymphocyte reconstitution occurred within 6 months (Table 2 ), 1 year after transplant MM patients had a significantly greater median number of CD19 cells/l (207, range: 99-729) than CML patients (58, range: 7-490) (P = 0.007) (Figure 1) . Notably, no B-lymphoproliferative disorders occurred after transplant.
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Immune reconstitution according to GVHD
Twelve out of 30 evaluable patients developed acute GVHD grade II-IV, whereas 13 of 27 patients developed chronic GVHD. Interestingly, only 27% MM patients as opposed to 55% of patients with myeloproliferative diseases experienced acute GVHD grade II-IV, whereas the incidence of chronic GVHD was similar in the three groups of patients.
Analysis of CD3 + T cell number in patients with acute GVHD grade II-IV (GVHD+), or without (GVHD−), revealed that the overall number of these cells is generally higher in GVHD− patients after transplant (data not shown). However, median absolute numbers of CD4 + and CD8 + T cells in patients that did not experience acute GVHD II-IV were higher than those of patients with acute GVHD уgrade II at any time-point evaluated (Figure 2 , right), while the CD4:CD8 ratio increased 1 year after transplant in both groups with no difference (Figure 2, left) .
Therefore, we tested the hypothesis of whether the better immune reconstitution of CD4 + T cells previously shown in MM patients could be due to the lower rate of acute GVHD in these patients. After excluding from the analysis all the patients who developed an acute GVHD grade II-IV, we evaluated the median CD4 + T cell number in MM patients as opposed to patients with myeloproliferative disorders. Interestingly, 1 year after transplant MM patients with GVHD Ͻgrade II still showed a median CD4 + T cell number significantly (P = 0.05) higher than patients with myeloproliferative diseases and with GVHD Ͻgrade II (Figure 3) , thus suggesting that GVHD does not seem to be related to the different T cell reconstitution among MM, CML and AML patients after allogeneic PBSC transplantation.
Discussion
Hematopoietic stem cells obtained from mobilized peripheral blood allow a more rapid immune reconstitution as compared to those obtained from bone marrow, both in the autologous and in the allogeneic setting. 4, 5, 15 Despite this finding, it is still controversial whether it is related to the higher number of CD34 + cells or to the higher number of T cells in the graft. 16, 17 It is difficult to compare previous studies because of the high variability in the number of T cells infused with unmanipulated G-CSF mobilized PBSC. 4, [16] [17] [18] However, recent findings on the thymic output in adult patients after autologous PBSC transplantation, by measuring the number of T cell receptor rearrangement excision circles (TREC), 19 might prompt new studies on the role of donor stem cells in contributing to the host immune reconstitution, both quantitatively and qualitatively.
In this study we addressed the hypothesis of whether patients with different diseases may show any difference in the kinetics of lymphocyte reconstitution following allogeneic PBSC transplantation from an HLA-identical sibling. We observed that MM patients have a faster and greater CD4
+ T cell recovery as compared to AML and CML patients. In particular, these latter patients seem to have the worst overall immune reconstitution with the lowest number of CD4 + T cells, comparable to AML patients, but also with the lowest number of CD8 + T, NK and B cells. Because of the very low incidence of lethal infections in this series of patients no correlation could be found between the number of T cells and major infectious complications.
The different pattern of immune reconstitution in the three groups of patients is unlikely to be due to the con- ditioning regimen since the majority of AML patients were prepared with the same drugs as CML patients. Also, despite a previous study suggesting that more immunosuppressive conditioning regimens, such as Bu/Cy or Cy/TBI, would affect the CD8 + T cell reconstitution, 20 this does not apply to our findings since the majority of MM patients received a preparative regimen including TBI/Cy and melphalan, whereas other patients received mainly a Bu/Cybased treatment. On the contrary, in this study it seems paradoxically that by using PBSC as source of allogeneic stem cells, TBI might correlate with CD4 + T cell recovery. Nonetheless, a greater number of patients will be required to confirm this hypothesis.
Among other factors previously related to the immune reconstitution after bone marrow transplant there is the total number of mononuclear cells infused. 20 In our study, as in the majority of allogeneic transplants with PBSC, high numbers of mononuclear cells, as well as of CD34 + cells, have been given to all the recipients of PBSC, as it is also demonstrated by not finding any difference in the time to engraftment for ANC and platelets in the three groups of patients we analyzed. Accordingly, the total number of Bone Marrow Transplantation
CD3
+ T cells infused was also high and did not differ among the three groups significantly.
In contrast with a previous report, 18 we demonstrated that patients with acute GVHD have lower numbers of both CD4
+ and CD8 + T cells. Therefore, since it appears that the impairment of T cell recovery in patients developing GVHD is not selective of one T cell subset, the CD4:CD8 ratio is comparable in patients with or without GVHD, suggesting that this parameter perhaps should not be of value in considering the T cell reconstitution after transplant. However, T cell reduction in patients developing acute GVHD grade II-IV is not totally unexpected due to more aggressive immunosuppressive treatments, such as high dose prednisone, and/or anti-thymocyte globulin (ATG), and/or mycophenolate mofetil (MMF). Furthermore, it is not known whether a smaller number of circulating T cells may also be due to a higher lymphocyte infiltration of GVHD target organs. A third hypothesis may be related to a higher rate of apoptotic T cells in patients with GVHD due to an enhanced Fas:FasL interaction. 21 Interestingly, even after excluding all the patients with acute GVHD Ͼgrade I, 12 months after transplant MM patients showed higher CD4 + T cell values than patients with myeloproliferative diseases. This observation, together with a better selection of the patients and a more appropriate timing for transplant, may further support promising results of PBSC allogeneic transplantation in MM. 9, 10 Also, future studies will address the hypothesis of whether the rapid immune reconstitution in these patients might improve the clinical outcome both by reducing infectious episodes and by increasing an immune antitumor reactivity, on the basis of previous demonstration of a graft-versusmyeloma effect. 22, 23 However, at this time, studies on the antitumor effect of G-CSF-mobilized T cells are still warranted because of the immunological differences between peripheral blood cells before and after G-CSF treatment. 24 In fact, previous experimental studies demonstrated that G-CSF might affect the cytotoxic T cell activity by inducing human lymphocytes to preferentially release type 2 cytokines (IL-4, IL-5 and IL-10) rather than type 1 (IFN-␥, TNF-␣ and IL-2) upon activation. [25] [26] [27] [28] In particular, it has recently been shown that PBSC are enriched in circulating dendritic cells type 2 (DC2), that are capable of presenting the antigen and stimulating Th2 T cells. 29 Therefore, donor DC2 might facilitate allogeneic engraftment by reducing the host antidonor cytotoxicity across HLA barrier. Moreover, they might down-modulate the donor anti-host reactivity by driving donor T cells to Th2. Since it is still unclear if donor DC may play a role in allogeneic transplantation, [30] [31] [32] we are currently investigating whether a correlation between the number of donor DC, both DC1 and DC2, and the immune recovery, as well as the development of GVHD, can be observed. Particularly, we will address whether in MM patients, as opposed to other patients undergoing an allogeneic PBSC transplantation, rapid CD4 + lymphocyte reconstitution can parallel the recovery of a subset of circulating DC.
